Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 4%, reaching HKD 8.36 with a trading volume of HKD 579 million, following the announcement of positive results from a Phase III clinical trial for its biosimilar drug, Sichuqi You Injection [1] Group 1: Clinical Trial Results - CSPC's subsidiary, CSPC Zhongqi Biopharmaceutical Co., Ltd., announced that its drug, Sichuqi You Injection, achieved positive topline results in a Phase III clinical trial for treating moderate to severe plaque psoriasis [1] - The study met its primary endpoint, demonstrating clinical equivalence to the reference drug, Cosentyx, with good safety profiles and no new or unexpected safety signals [1] - The drug is a fully human IgG1 monoclonal antibody and is expected to meet long-term safety needs for patients [1] Group 2: Product Background - Sichuqi You Injection is a biosimilar to Cosentyx, which has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1]
港股异动 | 石药集团(01093)再涨超4% 司库奇尤单抗注射液III期临床试验取得顶线分析数据